Ainos, Inc. AIMDW
0.05 USD 0.00 (+0.00%)
Nov 4, 2026, 2:36 PM EST
0.0391 Day range 0.0462
0.0391 52-week range 0.0462
- YTD
- 0.00%
- 1 year
- 0.00%
News
benzinga.com Ainos Announces AI Nose Platform Hits Over 3B Chemical Data Points Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that its AI Nose platform has accumulated more than 3 billion real-world chemical data points, surpassing three times
benzinga.com Ainos Completes Required Data Delivery And Technology Transfer Under Its VELDONA License Deal For $600K Initial License Payment Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has completed the required data delivery and technology transfer under its VELDONA® license agreement,
benzinga.com Ainos Receives Three New Japanese Patents For Its AI Nose Technologies Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has secured three new Japanese patents covering AI Nose technologies and their integration with robotic…
benzinga.com Ainos’ AI Nose Platform Surpasses 878M Real-World Smell And Chemical Data Points, Primarily Generated From Semiconductor Manufacturing And Real-World Operating Environments Dataset expands by approximately 265 million data points since July 21 as continued AI Nose system deployment across semiconductor manufacturing environments accelerates Ainos' Real-World Data…
benzinga.com Ainos Notes Review Of Its One-Year, AI-Analyzed Breath Pattern Study Focusing On Chronic Obstructive Pulmonary Disease Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a Smell AI company digitizing scent into machine-readable data for artificial intelligence applications, today highlighted a new…- benzinga.com Ainos Activates Phased Industrial Deployment Roadmap To Install Up To 20K AI Nose Units Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced the activation of a phased industrial deployment roadmap under a strategic framework that contemplates the…
- benzinga.com Ainos Collaborates With Mirle Automation To Integrate Ainos' AI Platform Into Robots, Quadruped Robots Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced a technology…
benzinga.com Ainos And Trusval Technology Agree To Establish Distribution And Deployment Partnership Within Defined Scope Of Semiconductor Front-End Manufacturing Applications Partnership Supports Ainos' 2026 Strategic Focus on Advancing AI Nose Upstream and Accelerating Scent Data Accumulation in Advanced Wafer FabsHOUSTON, TX / ACCESS Newswire / January 7, 2026 / Ainos,…- benzinga.com Ainos Collaborates With NEXCOM International To Integrate Ainos' AI Nose Technology With NEXCOM's Industrial Edge Computing Platforms SAN DIEGO, CALIFORNIA / ACCESS Newswire / October 14, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a leader in AI-powered scent digitization, today announced a strategic partnership with NEXCOM…
benzinga.com Ainos Secures Seven New Patents In Europe, Germany, Taiwan, And China, Enhancing Its AI Nose Digital Olfaction Platform For Robotics Applications Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced it has secured seven new patents in Europe, Germany, Taiwan and China…- benzinga.com Ainos Launches Patented AI Nose Platform For Industrial And Healthcare Markets, Unveils SmellTech-As-A-Service At Automation Taipei 2025 Patented AI Olfaction Platform Targets Semiconductor, Smart Factory, and Hospital Markets With First Deployments UnderwaySmellTech-as-a-Service Subscription Delivers AI Upgrades and Analytics,…
benzinga.com Ainos, Inc Announces Its Investigational Low-Dose Oral Interferon-Alpha Drug Candidate, Veldona Has Received Formal Approval From Taiwan's Food And Drug Administration To Initiate A Clinical Study For Primary Sjögren's Syndrome Advancing a Novel, Side-Effect-Free Treatment for a Rare Yet Widely Underserved Autoimmune Disease